CV Sciences Inc (CVSI)

[Deetew]

Response to Robbins Arroyo LLP complaint

Source Robbins Arroyo LLP

"According to the complaint, CV Sciences touted that CVSI-007 had a market estimated at "greater than $2 billion," demonstrating the importance of CVSI-007 to the company's operations."

First off, claiming that the patent-pending CVSI-007 has a market segment worth greater than $2 Billion doesn't actually demonstrate anything about the patent's importance to operations. The patent-pending item brought in zero dollars in revenue, so at the present time, CVSI-007 isn't of material importance to operations since CVSI's core revenue comes from its hemp-derived CBD line of products. Now, if CVSI-007 was CVSI's only product, then that would be another story. Since the plaintiff's argument can easily be destroyed by demonstrating with a balance sheet (essentially) that CVSI-007 is not of significant importance to operations, CVSI doesn't have to notify investors about non-final "final" rejections. --Especially in light of the fact that CVSI's patent is STILL pending, and according to patent rules from USPTO, all final rejections are automatically withdrawn upon successful patent appeal. These parasite plaintiffs are going to lose great deals of money, and I would expect a counterclaim to be filed against them since Citron research failed to notify investors on Aug. 20th, 2018 that CVSI's patent was still indeed "pending."

Observe